Polycystic ovary syndrome presents a multisystem endocrine disorder requiring integrated assessment across hormonal, metabolic, reproductive, and psychological domains. UK clinicians diagnose it using Rotterdam criteria (two of three: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound), after excluding mimics such as thyroid dysfunction or hyperprolactinaemia.
Presentation often occurs in adolescence or early adulthood with irregular menses, hirsutism, acne, or infertility. Historical male-biased research frameworks have contributed to diagnostic delays, as symptoms were sometimes framed through general rather than sex-specific lenses. Lifetime risks include insulin resistance (common), progression to type 2 diabetes, and elevated cardiovascular markers. Pregnancy complications such as gestational diabetes, hypertensive disorders, preterm birth, and caesarean delivery show increased odds.
Management begins with lifestyle optimisation. Pharmacological options include combined oral contraceptives for cycle regulation and androgen suppression, metformin for metabolic features where indicated, and clomifene or letrozole for ovulation induction. Long-term monitoring should address metabolic and cardiovascular risk, with attention to psychological wellbeing given higher reported rates of anxiety and depression.
NICE and international guidelines emphasise holistic, life-course care rather than siloed symptom management. Variation persists in testing sequences, ultrasound reliance, and follow-up, particularly for adolescents where diagnosis requires caution (typically after two years post-menarche).
Women’s Health Hubs and the renewed Women’s Health Strategy seek to improve access and coordination, shifting more care toward primary and community settings while addressing gynaecology waiting times and fragmented pathways.
Internal links: See clinical perspectives on endometriosis and chronic pelvic pain and maternity safety.
References
- National Institute for Health and Care Excellence. Polycystic ovary syndrome: diagnosis and management.
- RCOG / International PCOS Guideline 2023.
- NHS England Women’s Health Strategy.
- NIHR evidence reviews.
- Relevant primary care pathways
Mandatory disclaimer
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.